Anaemia management strategies: optimising treatment using epoetin beta (NeoRecormon).

Anemia, Iron-Deficiency/blood/chemically induced/drug therapy; Antineoplastic Combined Chemotherapy Protocols/administration & dosage/adverse effects; Drug Therapy, Combination; Erythropoietin, Recombinant/therapeutic use; Hematologic Neoplasms/drug therapy; Humans; Iron Compounds/administration & dosage; Multivariate Analysis; Neoplasms/blood/drug therapy; Predictive Value of Tests; Quality of Life; Treatment Outcome

Abstract :

[en] Anaemia has a detrimental impact on quality of life and it is important that this condition is recognised and treated in patients with cancer. Epoetin beta is an effective and well-tolerated treatment of anaemia in patients with a wide range of solid and haematological malignancies. A study in patients with lymphoid malignancies confirms that epoetin beta is equally effective at the same overall weekly dose (30,000 IU weekly) when given once-weekly or three-times weekly. This once-weekly regimen has also proved effective in patients with solid tumours. Once-weekly treatment is more convenient for the patient, potentially improving compliance and is associated with reduced hospital administration costs. The majority of patients with cancer will respond to epoetin therapy with an increase in haemoglobin levels. However, it is of value to identify those patients who are likely to respond, so that cost-effectiveness can be improved. Despite much research into potential predictive factors, follow-up studies are required and clinical judgement remains key to managing the anaemia of cancer. In addition, studies suggest that intravenous iron supplementation can improve response to epoetin therapy in patients with functional iron deficiency. Epoetin beta offers an effective, safe and convenient therapy for the management of anaemia in patients with cancer. Ongoing studies are expected to lead to a greater understanding of the optimal use of epoetins in cancer-related anaemia.

Disciplines :

Hematology

Author, co-author :

Glaspy, John

Beguin, Yves ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique

Language :

English

Title :

Anaemia management strategies: optimising treatment using epoetin beta (NeoRecormon).

Publication date :

2005

Journal title :

Oncology

ISSN :

0030-2414

eISSN :

1423-0232

Publisher :

Karger, Basel, Switzerland

Volume :

69 Suppl 2

Pages :

8-16

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 25 February 2009

Statistics

Number of views

138 (1 by ULiège)

Number of downloads

161 (1 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Groopman JE, Itri LM: Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999;91:1616-1634.
Ludwig H, Van Belle S, Barrett-Lee P, Birgegård G, Bokemeyer C, Gascón P, Kosmidis P, Krzakowski M, Nortier J, Olmi P, Schneider M, Schrijvers D: The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004;40:2293-2306.
Cella D: Factors influencing quality of life in cancer patients: anemia and fatigue. Semin Oncol 1998;25:43-46.
Goodnough LT, Brecher ME, Kanter MH, Au-Buchon JP: Transfusion medicine. First of two parts-blood transfusion. N Engl J Med 1999;340:438-447.
Lin FK, Suggs S, Lin CH, Browne JK, Smalling R, Egrie JC, Chen KK, Fox GM, Martin F, Stabinsky Z, Badrawi SM, Lai P-H, Goldwasser E: Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci USA 1985;82:7580-7584.
Winearls CG, Oliver DO, Pippard MJ, Reid C, Downing MR, Cotes PM: Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 1986;2:1175-1178.
Ludwig H, Fritz E, Kotzmann H, Höcker P, Gisslinger H, Barnas U: Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 1990;322:1693-1699.
Jelkmann W: Molecular biology of erythropoietin. Intern Med 2004;43:649-659.
Glimelius B, Linne T, Hoffman K, Larsson L, Svensson JH, Nasman P, Svensson B, Helmers C: Epoetin beta in the treatment of anemia in patients with advanced gastrointestinal cancer. J Clin Oncol 1998;16:434-440.
Bogdanos J, Karamanolakis D, Milathianakis K, Repousis P, Chloraki-Bobota A, Majed H, Pagalou-Thoua E, Tsintavas A, Koutsilieris M: Epoetin beta (NeoRecormon) corrects anaemia in patients with hormone-refractory prostate cancer and bone metastases. Anticancer Res 2004;24:1957-1961.
Boogaerts M, Coiffier B, Kainz C, Epoetin β QOL Working Group: Impact of epoetin β on quality of life in patients with malignant disease. Br J Cancer 2003;88:988-995.
Österborg A, Brandberg Y, Molostova V, Iosava G, Abdulkadyrov K, Hedenus M, Messinger D, Epoetin Beta Hematology Study Group: Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. J Clin Oncol 2002;20:2486-2494.
Kunikane H, Watanabe K, Fukuoka M, Saijo N, Furuse K, Ikegami H, Ariyoshi Y, Kishimoto S: Double-blind randomized control trial of the effect of recombinant human erythropoietin on chemotherapy-induced anemia in patients with non-small cell lung cancer. Int J Clin Oncol 2001;6:296-301.
ten Bokkel Huinink WW, de Swart CA, van Toorn DW, Morack G, Breed WP, Hillen HF, van der Hoeven JJ, Reed NS, Fairlamb DJ, Chan SY, Godfrey KA, Kristensen GB, van Tinteren H, Ehmer B: Controlled multicentre study of the influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy. Med Oncol 1998;15:174-182.
Ordóñez A, Isla D, Sánchez A, Arrivi A, Manzano JL: Prevention of anaemia in patients with solid tumours receiving platinum-based chemotherapy: the NeoPrevent study. Ann Oncol 2004;15(suppl 3):abstract 843P.
Oberhoff C, Neri B, Amadori D, Petry KU, Gamucci T, Rebmann U, Nowrousian MR, Voigtmann R, Monfardini S, Armand JP, Herrmann R, Netter-Pinon J, Tubiana-Mathieu N, Zwierzina H: Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: a randomized, controlled study. Ann Oncol 1998;9:255-260.
Olsson AM, Svensson JH, Sundstrom J, Bergstrom S, Edekling T, Carlsson G, Hansen J, Svensson B, Albertsson M: Erythropoietin treatment in metastatic breast cancer - effects on Hb, quality of life and need for transfusion. Acta Oncol 2002;41:517-524.
Cazzola M, Beguin Y, Kloczko J, Spicka I, Coiffier B: Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. Br J Haematol 2003;122:386-393.
Coiffier B, Milpied N, Facon T, Beris P: Epoetin beta (NeoRecormon) once weekly or three-times weekly produces a rapid haemoglobin response in anaemic patients with lymphoproliferative malignancies. Hematol J 2004;5:abstract 551.
Leonard RC, Aapro M, Chan S, Dirix LY, Mayordomo J, Reichert D, Untch M: Once weekly epoetin beta in patients with metastatic breast cancer receiving anthracycline- or taxane-based chemotherapy. Ann Oncol 2004;15:abstract 188P.
Salles G, Facon T, Hunault-Berger M, Rachieru P, Spaeth D, Fiorentini P, Bergougnoux L: Efficacy of epoetin beta (NeoRecormon®) 30,000 IU once weekly in anemic patients with non-myeloid malignancies receiving chemotherapy. Haematologica/Hematol J 2005;90(suppl 2):abstract 1157.
Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, Einhorn LH: Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001;19:2875-2882.
Witzig TE, Silberstein PT, Loprinzi CL, Sloan JA, Novotny PJ, Mailliard JA, Rowland KM, Alberts SR, Krook JE, Levitt R, Morton RF: Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol 2005;23:2606-2617.
Hedenus M, Adriansson M, San Miguel J, Kramer MH, Schipperus MR, Juvonen E, Taylor K, Belch A, Altes A, Martinelli G, Watson D, Matcham J, Rossi G, Littlewood TJ, Darbepoetin Alfa 20000161 Study Group: Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol 2003;122:394-403.
Vansteenkiste J, Pirker R, Massuti B, Barata F, Font A, Fiegl M, Siena S, Gateley J, Tomita D, Colowick AB, Musil J, Aranesp 980297 Study Group: Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002;94:1211-1220.
Demetri GD, Kris M, Wade J, Degos L, Cella D, Procrit Study Group: Quality-of-life benefits in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. J Clin Oncol 1998;16:3412-3425.
Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B, Epoetin Alfa Study Group: Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:2865-2874.
Glaspy J, Degos L, Dicato M, Demetri GD: Comparable efficacy of epoetin alfa for anemic cancer patients receiving platinum- and non-platinum-based chemotherapy: a retrospective subanalysis of two large, community-based trials. Oncologist 2002;7:126-135.
Boogaerts M, Oberhoff C, ten Bokkel Huinink W, Nowrousian MR, Hayward C, Burger H-U: Epoetin beta (NeoRecormon®) therapy in anaemic cancer patients receiving platinum and non-platinum chemotherapy. Haematologica/Hematol J 2005;90(suppl 2):abstract 1134.
Österborg A, Boogaerts MA, Cimino R, Essers U, Holowiecki J, Juliusson G, Jäger G, Najman A, Peest D: Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma - a randomized multicenter study. Blood 1996;87:2675-2682.
Cazzola M, Messinger D, Battistel V, Bron D, Cimino R, Enller-Ziegler L, Essers U, Greil R, Grossi A, Jager G, LeMevel A, Najman A, Silingard V, Spriano M, van Hoof A, Ehmer B: Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response. Blood 1995;86:4446-4453.
Bokemeyer C, Aapro MS, Coirdi A, Foubert J, Link H, Österborg A, Repetto L, Soubeyren P: EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 2004;40:2201-2216.
Beguin Y, Clemons GK, Pootrakul P, Fillet G: Quantitative assessment of erythropoiesis and functional classification of anemia based on measurements of serum transferrin receptor and erythropoietin. Blood 1993;81:1067-1076.
Cazzola M, Ponchio L, Pedrotti C, Farina G, Cerani P, Lucotti C, Novella A, Rovati A, Bergamaschi G, Beguin Y: Prediction of response to recombinant human erythropoietin (rHu Epo) in anemia of malignancy. Haematologica 1996;81:434-441.
Beguin Y: Prediction of response and other improvements on the limitations of recombinant human erythropoietin therapy in anemic cancer patients. Haematologica 2002;87:1209-1221.
Cazzola M, Mercuriali F, Brugnara C: Use of recombinant human erythropoietin outside the setting of uremia. Blood 1997;89:4248-4267.
Henry DH: Supplemental iron: a key to optimizing the response of cancer-related anemia to rHuEPO? Oncologist 1998;3:275-278.
Thomas C, Thomas L: Biochemical markers and hematologic indices in the diagnosis of functional iron deficiency. Clin Chem 2002;48:1066-1076.
Fishbane S, Ungureanu VD, Maesaka JK, Kaupke CJ, Lim V, Wish J: The safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis 1996;28:529-534.
Cavill I: Intravenous iron as adjuvant therapy: a two-edged sword? Nephrol Dial Transplant 2003;18:viii24-viii28.
Stevens RG, Graubard BI, Micozzi MS, Neriishi K, Blumberg BS: Moderate elevation of body iron level and increased risk of cancer occurrence and death. Int J Cancer 1994;56:364-369.
Weinberg ED: The role of iron in cancer. Eur J Cancer Prev 1996;5:19-36.
Macdougall IC, Tucker B, Thompson J, Tomson CR, Baker LR, Raine AE: A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 1996;50:1694-1699.
Glaspy J, Cavill I: Role of iron in optimizing responses of anemic cancer patients to erythropoietin. Oncology 1999;13:461-473.
Auerbach M, Ballard H, Trout JR, McIlwain M, Ackerman A, Bahrain H, Balan S, Barker L, Rana J: Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol 2004;22:1301-1307.
Henry DH, Dahl NV, Auerbach M, Tchekmedyian S, Laufman LR, Ferrlecit Cancer Study Group: Intravenous ferric gluconate (FG) for increasing response to epoetin (EPO) in patients with anemia of cancer chemotherapy - results of a multicenter, randomized trial. Blood 2004;104:abstract 3696.